MCID: ANS011
MIFTS: 56

Anus Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Anus Cancer

MalaCards integrated aliases for Anus Cancer:

Name: Anus Cancer 12 15
Anal Cancer 12 52 42
Malignant Neoplasm of Anus 71
Malignant Anal Tumor 12
Cancer of the Anus 52
Anus Neoplasms 71
Anal Carcinoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:14110
ICD9CM 34 154.2 154.3
NCIt 49 C7379
SNOMED-CT 67 93669004 93676009
ICD10 32 C21.0 C21.1
UMLS 71 C0003463 C0153445 C0153446 more

Summaries for Anus Cancer

NIH Rare Diseases : 52 Anal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the anus . Signs and symptoms of the condition include rectal bleeding ; a lump in or near the anus; anal pain; itching; changes in bowel habits; and/or swollen lymph nodes . In most cases, the underlying cause of anal cancer is unknown. There appears to be a link between anal cancer and the human papillomavirus (HPV) infection. Other risk factors for anal cancer include HIV infection, sexual activity, smoking, and a weakened immune system . The best treatment options for anal cancer depend on many factors including the stage of the condition, the location of the tumor and if there are associated conditions (i.e. HIV) but may include surgery, chemotherapy , and radiation therapy .

MalaCards based summary : Anus Cancer, also known as anal cancer, is related to squamous cell papilloma and anal squamous cell carcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Anus Cancer is CD4 (CD4 Molecule), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and PI3K-Akt signaling pathway. The drugs Oxaliplatin and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include anus, testes and lymph node, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A large intestine cancer that is located in the anus.

MedlinePlus : 42 The anus is where stool leaves your body when you go to the bathroom. It is made up of your outer layers of skin and the end of your large intestine. Anal cancer is a disease in which cancer cells form in the tissues of the anus. Anal cancer is rare. It is more common in smokers and people over 50. You are also at higher risk if you have HPV, have anal sex, or have many sexual partners. Symptoms include bleeding, pain, or lumps in the anal area. Anal itching and discharge can also be signs of anal cancer. Doctors use tests that examine the anus to diagnose anal cancer. They include a physical exam, endoscopy, ultrasound, and biopsy. Treatments include radiation therapy, chemotherapy, and surgery. NIH: National Cancer Institute

Wikipedia : 74 Anal cancer is a cancer which arises from the anus, the distal opening of the gastrointestinal tract.... more...

Related Diseases for Anus Cancer

Diseases related to Anus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 416)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 31.1 TP53 HRAS
2 anal squamous cell carcinoma 30.9 TP53 PIK3CA H2AC18 DCXR CDKN2A APOLD1
3 syphilis 30.9 CD8A CD4 CARTPT
4 papilloma 30.8 UBE3A TP53 KRAS EGFR CDKN2A CD4
5 cervix uteri carcinoma in situ 30.7 TP53 GP6 GP5 CDKN2A
6 squamous cell carcinoma 30.6 TP53 SERPINB3 PIK3CA HRAS EGFR CDKN2A
7 basaloid squamous cell carcinoma 30.6 TP53 EGFR CDKN2A
8 malignant anus melanoma 30.5 HRAS APOLD1
9 verrucous carcinoma 30.5 TP53 EGFR CDKN2A
10 in situ carcinoma 30.5 TP53 HRAS H2AC18 EGFR CDKN2A
11 vaginal cancer 30.5 UBE3A TP53 GP5 CDKN2A
12 anus benign neoplasm 30.5 H2AC18 CDKN2A APOLD1
13 mucinous adenocarcinoma 30.3 TP53 KRAS EGFR CDKN2A
14 adenocarcinoma 30.2 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
15 transitional cell carcinoma 30.0 TP53 HRAS EGFR CDKN2A
16 appendix adenocarcinoma 30.0 KRAS HRAS
17 vulva cancer 30.0 TP53 PIK3CA GP5 EGFR CDKN2A
18 anogenital venereal wart 29.8 UBE3A TP53 H2AC18 GP6 GP5 CDKN2A
19 lymphoma, non-hodgkin, familial 29.7 TP53 PIK3CA H2AC18 CDKN2A CD8A CD4
20 adenosquamous carcinoma 29.5 TP53 PIK3CA KRAS EGFR CD274
21 rectum adenocarcinoma 29.4 TP53 PIK3CA KRAS HRAS EGFR DCXR
22 cervical cancer 29.4 UBE3A TP53 SERPINB3 PIK3CA HRAS EGFR
23 exanthem 29.2 KRAS HRAS H2AC18 EGFR CD8A CD4
24 brain cancer 29.1 TP53 PIK3CA HRAS H2AC18 EGFR
25 penile cancer 29.0 TP53 PIK3CA KRAS HRAS GP5 EGFR
26 melanoma 29.0 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
27 squamous cell carcinoma, head and neck 28.9 TP53 PIK3CA HRAS H2AC18 EGFR CDKN2A
28 oropharynx cancer 28.1 UBE3A TP53 SERPINB3 PIK3CA HRAS H2AC18
29 obsolete: hiv-related anal cancer 12.2
30 anal canal carcinoma 11.5
31 hemorrhoid 11.5
32 anal margin squamous cell carcinoma 10.6 CDKN2A APOLD1
33 cork-handlers' disease 10.6 CD8A CD4
34 geotrichosis 10.6 CD4 CARTPT
35 syphilitic meningitis 10.6 CD8A CD4
36 vulvar intraepithelial neoplasia 10.6 TP53 CDKN2A
37 ventilation pneumonitis 10.6 CD8A CD4
38 malignant peritoneal mesothelioma 10.6 EGFR CDKN2A
39 cystoisosporiasis 10.6 CD4 CARTPT
40 diffuse infiltrative lymphocytosis syndrome 10.5 CD8A CD4
41 autoimmune lymphoproliferative syndrome, type iia 10.5 CD8A CD4
42 splenic flexure cancer 10.5 DCXR APOLD1
43 ovarian seromucinous carcinoma 10.5 TP53 CDKN2A
44 diabetes mellitus, insulin-dependent, 23 10.5 CD8A CD4
45 supraglottis cancer 10.5 SERPINB3 EGFR CDKN2A
46 esophageal basaloid squamous cell carcinoma 10.5 TP53 EGFR
47 esophagus verrucous carcinoma 10.5 TP53 EGFR CDKN2A
48 anal canal squamous cell carcinoma 10.5
49 esophageal candidiasis 10.5 CD8A CD4 CARTPT
50 mucocutaneous leishmaniasis 10.5 H2AC18 CD8A CD4

Comorbidity relations with Anus Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia

Graphical network of the top 20 diseases related to Anus Cancer:



Diseases related to Anus Cancer

Symptoms & Phenotypes for Anus Cancer

UMLS symptoms related to Anus Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, pruritus ani, gastrointestinal gas

GenomeRNAi Phenotypes related to Anus Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.01 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.01 KRAS
3 Decreased viability GR00221-A-1 10.01 EGFR HRAS KRAS PIK3CA CDKN2A INSRR
4 Decreased viability GR00221-A-2 10.01 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.01 HRAS CDKN2A
6 Decreased viability GR00221-A-4 10.01 EGFR PIK3CA CDKN2A
7 Decreased viability GR00301-A 10.01 KRAS INSRR
8 Decreased viability GR00381-A-1 10.01 KRAS
9 Decreased viability GR00402-S-2 10.01 EGFR HRAS KRAS PIK3CA CDKN2A INSRR

MGI Mouse Phenotypes related to Anus Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10 CARTPT CD4 CD8A CDKN2A EGFR HRAS
2 homeostasis/metabolism MP:0005376 9.97 CARTPT CD274 CD4 CDKN2A EGFR GP5
3 integument MP:0010771 9.7 CD274 CD4 CD8A CDKN2A EGFR GP6
4 no phenotypic analysis MP:0003012 9.28 CD274 CD4 CDKN2A EGFR HRAS KRAS

Drugs & Therapeutics for Anus Cancer

Drugs for Anus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 5310940 9887054 6857599 43805
2
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
4
nivolumab Approved Phase 3 946414-94-4
5
Pembrolizumab Approved Phase 3 1374853-91-4
6
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
7
Ipilimumab Approved Phase 3 477202-00-9
8
Cidofovir Approved Phase 3 113852-37-2 60613
9
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
10
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Antineoplastic Agents, Hormonal Phase 3
13 Cola Phase 3
14 Liver Extracts Phase 3
15 Analgesics Phase 3
16 Central Nervous System Depressants Phase 3
17 Narcotics Phase 3
18 Anesthetics, General Phase 3
19 Analgesics, Opioid Phase 3
20 Adjuvants, Anesthesia Phase 3
21 Anesthetics, Intravenous Phase 3
22 Anesthetics Phase 3
23 Adjuvants, Immunologic Phase 3
24 Interferon Inducers Phase 3
25 Anti-Infective Agents Phase 3
26 Antiviral Agents Phase 3
27 Anti-Bacterial Agents Phase 2, Phase 3
28 Alkylating Agents Phase 2, Phase 3
29 Antibiotics, Antitubercular Phase 2, Phase 3
30 Mitomycins Phase 2, Phase 3
31 Immunosuppressive Agents Phase 2, Phase 3
32 Antimetabolites Phase 2, Phase 3
33
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
34
Indinavir Approved Phase 2 150378-17-9 5362440
35
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
36
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
37
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
38
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
39
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
40
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
41
Durvalumab Approved, Investigational Phase 2 1428935-60-7
42
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
43
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
44
Pomalidomide Approved Phase 2 19171-19-8
45
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
46
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
47
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
48
Palonosetron Approved, Investigational Phase 2 135729-61-2, 135729-56-5, 119904-90-4 148211
49
protease inhibitors Phase 2
50 HIV Protease Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 216)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
3 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
4 Intensification Therapy for Locally Advanced Epidermoid Cancer of the Anal Canal - Phase III Intergroup Study Unknown status NCT00003652 Phase 3 cisplatin;fluorouracil
5 Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients With Anal Cancer Completed NCT00025090 Phase 3 cisplatin;fluorouracil;mitomycin C
6 A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer Completed NCT00075868 Phase 3 octreotide acetate
7 A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
8 A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults Completed NCT01164722 Phase 3
9 A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men and Women Completed NCT01461096 Phase 3
10 A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women Completed NCT01651949 Phase 3
11 An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men Completed NCT00090285 Phase 3
12 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Recruiting NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
14 ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study Recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
15 A Randomized Non-inferiority Trial Evaluating the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting NCT04157985 Phase 3 Continue PD-1/PD-L1 Inhibitors treatment
16 A Randomized Controlled Trial of a Carrageenan-Containing Lubricant to Reduce Transmission of Human Papillomavirus Infection Among Men Who Have Sex With Men Recruiting NCT02354144 Phase 2, Phase 3
17 Non-Inferiority Trial Comparing Immunogenicity From 1-Dose of Bivalent HPV Vaccine in Girls to 3-Doses of Quadrivalent Vaccine in Women: The PRIMAVERA-ESCUDDO Trial ("Puente de Respuesta Inmunologica Para Mejorar el Acceso a Vacunas y ERrAdicar el Cancer") Active, not recruiting NCT03728881 Phase 3
18 Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
19 A Phase III, Randomized, One-site, Pilot, Open-label, Parallel Groups Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males Not yet recruiting NCT04055142 Phase 3 cidofovir 1% topical ointment;sinecatechins 10% topical ointment
20 Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
21 An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
22 Phase II Nonrandomized Multicenter Study of the Impact of Radiochemotherapy (65 Gy + Cisplatin + 5FU) Combined With Cetuximab in Patients Presenting With Locally Advanced Anal Cancer Unknown status NCT00955240 Phase 2 cisplatin;fluorouracil
23 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
24 Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma Completed NCT00324415 Phase 2 cisplatin;fluorouracil
25 Phase II Study for Treatment of Anal HSIL Through Use of a Chinese Herbal Topical Cream Completed NCT00622440 Phase 2 AIJP (Arnebia Indigo Jade Pearl);Placebo
26 A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals Completed NCT00052897 Phase 1, Phase 2
27 A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men Completed NCT00428285 Phase 2
28 A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
29 A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
30 Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging Completed NCT01717391 Phase 2 fluorothymidine F 18
31 Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women Completed NCT00550589 Phase 2 cidofovir
32 AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males Completed NCT01209325 Phase 2
33 Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
34 A Phase II Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
35 Therapeutic Vaccination Against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT01923116 Phase 1, Phase 2 HPV-16 vaccine
36 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
37 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
38 A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer Recruiting NCT03233711 Phase 2
39 Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer Recruiting NCT03381352 Phase 2 Capecitabine;Mitomycin C
40 A Prospective Pilot Study to Evaluate the Feasibility of Intensity Modulated Proton Therapy in Reducing Toxicity in Anal Cancer Recruiting NCT03018418 Phase 2 Chemotherapy
41 A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma Recruiting NCT03519295 Phase 2 MPDL3280A;mDCF
42 A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients Recruiting NCT02865135 Phase 1, Phase 2 DPX-E7 vaccine
43 A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Refractory Metastatic Anal Cancer Recruiting NCT02919969 Phase 2 Pembrolizumab
44 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) Recruiting NCT02628067 Phase 2
45 A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) Recruiting NCT04166318 Phase 2 Capecitabine;Fluorouracil;Mitomycin
46 A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons Recruiting NCT02437851 Phase 2
47 M7824 in Subjects With HPV Associated Malignancies Recruiting NCT03427411 Phase 2 M7824
48 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Feasibility Trial Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
49 A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT) Recruiting NCT03870607 Phase 2
50 A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies Recruiting NCT03221400 Phase 1, Phase 2 PEN-866 Sodium

Search NIH Clinical Center for Anus Cancer

Genetic Tests for Anus Cancer

Anatomical Context for Anus Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Anus Cancer:

19
Anus

MalaCards organs/tissues related to Anus Cancer:

40
Testes, Lymph Node, Skin, Lung, Colon, Breast, T Cells

Publications for Anus Cancer

Articles related to Anus Cancer:

(show top 50) (show all 2060)
# Title Authors PMID Year
1
Elevation of Serum CEA in Patients with Squamous Cell Carcinoma of the Anus. 61 42
31319725 2019
2
Does race impact survival for patients with anal squamous cell carcinoma? 42
31549446 2019
3
HPV related cloacogenic carcinoma of the anal canal with divergent histomorphology. 42
31361242 2019
4
Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status. 61
31173641 2020
5
Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer. 61
30980294 2020
6
Dosimetric comparison of organs at risk using different contouring guidelines for definition of the clinical target volume in anal cancer. 61
32016496 2020
7
Satisfaction with high-resolution anoscopy for anal cancer screening among men who have sex with men: a cross-sectional survey in Abuja, Nigeria. 61
32024521 2020
8
Prevalence and associations of larger burden of intra-anal high-grade squamous intraepithelial lesions at baseline in an Australian cohort of gay and bisexual men: The Study of the Prevention of Anal Cancer. 61
31918181 2020
9
Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers. 61
31816512 2020
10
Systematic review of clinical practice guidelines for colorectal and anal cancer: the extent of recommendations for managing long-term symptoms and functional impairments. 61
32025805 2020
11
Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy. 61
32036405 2020
12
Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. 61
31959338 2020
13
Staging of Anal Cancer: Role of MR Imaging. 61
31753232 2020
14
Shared decision-making around anal cancer screening among black bisexual and gay men in the USA. 61
30931831 2020
15
Determining Optimal Follow-up for Patients With Anal Cancer Following Chemoradiation. 61
32028341 2020
16
Treatment efficacy for human papillomavirus-related anal squamous cell dysplasia in an under-represented population: human immunodeficiency-negative, non-men having sex with men, and non-transplant population. 61
31344295 2020
17
A Cell-Based Renilla Luminescence Reporter Plasmid Assay for High-Throughput Screening to Identify Novel FDA-Approved Drug Inhibitors of HPV-16 Infection. 61
31361520 2020
18
A rigorous exploration of anal HPV genotypes using a next-generation sequencing (NGS) approach in HIV-infected men who have sex with men at risk for developing anal cancer. 61
31769225 2020
19
Diagnosing uncertainty: The challenges of implementing medical screening programs for minority sub-populations in Canada. 61
31698281 2020
20
Early Detection of Anal High-Grade Squamous Intraepithelial Lesion: Do We Have an Impact on Progression to Invasive Anal Carcinoma? 61
31860581 2020
21
Recurrence of Anal High-Grade Squamous Intraepithelial Lesions among Women Living with HIV. 61
31977596 2020
22
Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014). 61
31932755 2020
23
Factors associated with anal cancer screening uptake in men who have sex with men living with HIV: a cross-sectional study. 61
31283539 2020
24
Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) - a prospective, randomized, 2-armed phase-II-trial. 61
31964381 2020
25
Establishing an Anal Cancer Screening Program in an Outpatient HIV Clinic: Referral Patterns and Patient Perceptions Survey. 61
31934806 2020
26
Anal cancer screening and Pap testing acceptability among HIV-positive men who have sex with men populations. 61
31945219 2020
27
Response to 'Anal cancer screening and Pap testing acceptability among HIV-positive men who have sex with men populations'. 61
31944396 2020
28
Assessment of Anal Cancer Screening Tools in Detecting High-Grade Anal Squamous Intraepithelial Lesions in Women. 61
31860580 2020
29
Prone positioning for peripherally inserted central catheter on a patient with anal cancer. 61
31232211 2020
30
The Utility of Digital Anal Rectal Examinations in a Public Health Screening Program for Anal Cancer. 61
31972661 2020
31
The prognostic role of FDG PET/CT before combined radio-chemotherapy in anal cancer patients. 61
31728763 2020
32
Detection of Anal Cancer at the Time of Neovaginoplasty: Is There a Role for Anal Cancer Screening Before Gender-Affirming Genital Surgery in High-Risk Patients? 61
31809234 2020
33
Risk of Anal Cancer Following Benign Anal Disease and Anal Cancer Precursor Lesions: A Danish Nationwide Cohort Study. 61
31597665 2020
34
Anal cancer prevention: Solving the puzzle piece by piece. 61
31977083 2020
35
Anal cancer in people living with HIV: A case series. 61
31842694 2020
36
Whither Anal Cancer? 61
31932753 2020
37
Delayed Diagnosis of Anal Cancer. 61
31420857 2020
38
Outcomes in immunosuppressed anal cancer patients. 61
31477240 2020
39
Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer. 61
31980834 2020
40
Nail squamous cell carcinoma: A hidden high-risk human papillomavirus reservoir for sexually transmitted infections. 61
30930083 2019
41
Recommendations Favoring Anal Cytology as a Method for Anal Cancer Screening: A Systematic Review. 61
31817212 2019
42
Socioeconomic disparities in timeliness of care and outcomes for anal cancer patients. 61
31595720 2019
43
Society of abdominal radiology disease-focused panel (DFP) on rectal and anal cancer: annual short report. 61
31587098 2019
44
Human papillomavirus, radiation dose and survival of patients with anal cancer. 61
31282249 2019
45
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). 61
31574418 2019
46
Topical application of a dual PI3K/mTOR inhibitor prevents anal carcinogenesis in a human papillomavirus mouse model of anal cancer. 61
30888976 2019
47
Rectal cancer lexicon: consensus statement from the society of abdominal radiology rectal & anal cancer disease-focused panel. 61
31388697 2019
48
mRNA Detection in Anal Cytology: A Feasible Approach for Anal Cancer Screening in Men Who Have Sex with Men Living With HIV. 61
31684110 2019
49
Rectal cancer MR staging: pearls and pitfalls at baseline examination. 61
31115601 2019
50
Anal prevalence of HPV in women with pre-malignant lesion or cancer in the cervix and anal canal simultaneously: cross-sectional study. 61
31353465 2019

Variations for Anus Cancer

Expression for Anus Cancer

Search GEO for disease gene expression data for Anus Cancer.

Pathways for Anus Cancer

Pathways related to Anus Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.42 UBE3A TP53 PIK3CA KRAS HRAS EGFR
2
Show member pathways
13.01 UBE3A TP53 PIK3CA KRAS HRAS EGFR
3
Show member pathways
12.97 TP53 PIK3CA KRAS HRAS EGFR CD4
4
Show member pathways
12.89 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
5 12.85 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
6
Show member pathways
12.82 TP53 PIK3CA KRAS HRAS CDKN2A
7
Show member pathways
12.8 TP53 PIK3CA KRAS INSRR HRAS EGFR
8
Show member pathways
12.74 TP53 PIK3CA KRAS HRAS EGFR
9
Show member pathways
12.74 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
10
Show member pathways
12.68 TP53 KRAS HRAS EGFR CD4
11 12.65 PIK3CA KRAS INSRR HRAS EGFR
12
Show member pathways
12.63 TP53 PIK3CA KRAS HRAS EGFR
13
Show member pathways
12.63 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
14
Show member pathways
12.53 TP53 PIK3CA KRAS HRAS EGFR CD4
15
Show member pathways
12.49 TP53 PIK3CA KRAS HRAS EGFR
16 12.45 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
17
Show member pathways
12.44 TP53 PIK3CA KRAS HRAS EGFR
18
Show member pathways
12.41 PIK3CA KRAS HRAS EGFR
19
Show member pathways
12.41 PIK3CA KRAS INSRR HRAS EGFR
20
Show member pathways
12.38 TP53 PIK3CA KRAS INSRR HRAS EGFR
21
Show member pathways
12.34 PIK3CA KRAS HRAS CD4
22
Show member pathways
12.3 PIK3CA KRAS HRAS EGFR
23 12.27 TP53 PIK3CA KRAS HRAS EGFR
24
Show member pathways
12.25 PIK3CA KRAS HRAS GP6
25
Show member pathways
12.24 PIK3CA KRAS HRAS EGFR CD8A CD4
26
Show member pathways
12.18 TP53 PIK3CA KRAS HRAS
27
Show member pathways
12.15 TP53 PIK3CA KRAS HRAS
28
Show member pathways
12.15 PIK3CA KRAS HRAS EGFR
29 12.14 TP53 PIK3CA KRAS HRAS CDKN2A CD4
30
Show member pathways
12.12 TP53 PIK3CA KRAS INSRR HRAS EGFR
31 12.1 TP53 PIK3CA KRAS HRAS CDKN2A
32
Show member pathways
12.09 PIK3CA KRAS HRAS EGFR
33
Show member pathways
12.07 TP53 KRAS HRAS EGFR
34 12.04 UBE3A TP53 PIK3CA KRAS HRAS CDKN2A
35 12.02 TP53 PIK3CA KRAS HRAS
36 12.02 TP53 PIK3CA KRAS HRAS
37
Show member pathways
11.95 PIK3CA KRAS HRAS EGFR
38 11.9 PIK3CA KRAS HRAS EGFR
39 11.86 TP53 PIK3CA KRAS HRAS CDKN2A
40
Show member pathways
11.84 PIK3CA KRAS HRAS EGFR
41
Show member pathways
11.82 PIK3CA KRAS HRAS
42 11.81 TP53 KRAS HRAS EGFR CDKN2A
43 11.75 TP53 PIK3CA CDKN2A
44 11.7 TP53 KRAS HRAS
45 11.69 PIK3CA KRAS HRAS
46 11.66 TP53 PIK3CA INSRR HRAS
47 11.63 KRAS HRAS EGFR
48 11.57 TP53 EGFR CDKN2A
49 11.54 KRAS HRAS EGFR
50 11.47 KRAS HRAS EGFR

GO Terms for Anus Cancer

Biological processes related to Anus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.76 SERPINB3 HRAS EGFR CD274
2 liver development GO:0001889 9.65 PIK3CA KRAS EGFR
3 positive regulation of protein phosphorylation GO:0001934 9.56 KRAS HRAS EGFR CD4
4 positive regulation of MAP kinase activity GO:0043406 9.54 KRAS HRAS EGFR
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.46 INSRR EGFR CD8A CD4
6 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 TP53 EGFR
7 enzyme linked receptor protein signaling pathway GO:0007167 9.4 GP6 CD4
8 cell surface receptor signaling pathway GO:0007166 9.35 HRAS EGFR CD8A CD4 CD274
9 response to isolation stress GO:0035900 9.32 KRAS HRAS
10 Ras protein signal transduction GO:0007265 8.92 TP53 KRAS HRAS CDKN2A

Molecular functions related to Anus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.13 SERPINB3 EGFR CD4
2 protein kinase binding GO:0019901 9.02 TP53 EGFR CDKN2A CD8A CD4

Sources for Anus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....